UY34465A - ?inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares?. - Google Patents

?inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares?.

Info

Publication number
UY34465A
UY34465A UY0001034465A UY34465A UY34465A UY 34465 A UY34465 A UY 34465A UY 0001034465 A UY0001034465 A UY 0001034465A UY 34465 A UY34465 A UY 34465A UY 34465 A UY34465 A UY 34465A
Authority
UY
Uruguay
Prior art keywords
alfa1
progression
beginning
delay
proteinase inhibitor
Prior art date
Application number
UY0001034465A
Other languages
English (en)
Inventor
Forshag Mark
Waltrip Royce
Garlinghouse Les
Barnett William
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of UY34465A publication Critical patent/UY34465A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0018—Details of inhalators; Constructional features thereof with exhalation check valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen procedimientos para demorar el comienzo o disminuir la progresión de exacerbaciones pulmonares mediante la administración de inhibidor de alfa1-proteinasa inhalado.
UY0001034465A 2011-12-30 2012-11-23 ?inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares?. UY34465A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161581708P 2011-12-30 2011-12-30

Publications (1)

Publication Number Publication Date
UY34465A true UY34465A (es) 2013-07-31

Family

ID=47470050

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034465A UY34465A (es) 2011-12-30 2012-11-23 ?inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares?.

Country Status (19)

Country Link
US (1) US9421248B2 (es)
EP (1) EP2758065B1 (es)
JP (4) JP2015504051A (es)
KR (1) KR20140108516A (es)
CN (2) CN107596359A (es)
AR (2) AR088971A1 (es)
AU (1) AU2012337241B2 (es)
BR (1) BR112014007127A2 (es)
CA (1) CA2844878C (es)
CL (1) CL2014000722A1 (es)
ES (1) ES2887358T3 (es)
HK (1) HK1198918A1 (es)
IL (1) IL231109B (es)
MX (1) MX351189B (es)
MY (1) MY166314A (es)
RU (1) RU2635482C2 (es)
SG (2) SG2014012066A (es)
UY (1) UY34465A (es)
WO (1) WO2013098672A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528234A (ja) * 2013-08-05 2016-09-15 フォールマン、ジェラルド 喫煙の悪影響を減らす新規手段
WO2016106291A1 (en) * 2014-12-22 2016-06-30 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
DK3253406T3 (da) * 2015-02-05 2024-01-22 Canem Holdings Llc Sammensætninger til behandling af granulomatose med polyangiitis
US10960062B2 (en) 2017-02-21 2021-03-30 Kamada Ltd. Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases
US10663434B2 (en) * 2017-03-31 2020-05-26 Sonix, Inc. Wafer chuck
WO2021028927A1 (en) * 2019-08-15 2021-02-18 Kamada Ltd Combination of alpha-1-antitrypsin and steroids and uses therefor
CA3174939A1 (en) * 2020-05-01 2021-11-04 Nikolay ZHUKOVSKY Treatment and/or prevention of a disease or a syndrome related to a virus infection

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE395611B (sv) 1975-12-12 1977-08-22 Draco Ab Aerosolinhalationsanordning avsedd for inhalering genom ett inhaleringsmunstycke av farmakologiskt aktiva substanser
SE411705B (sv) 1976-11-09 1980-02-04 Draco Ab Anordning for generering av en avskermad, vesentligen drivmedelsfri aerosol
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4667688A (en) 1983-11-28 1987-05-26 Francisco Roig Mini pack of cigarettes
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
WO1986000337A1 (fr) 1984-06-19 1986-01-16 Transgene S.A. DERIVES DE L'alpha1-ANTITRYPSINE HUMAINE ET PROCEDE POUR LEUR PREPARATION
US4697003A (en) 1985-11-01 1987-09-29 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US5114917A (en) 1986-12-24 1992-05-19 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US5915378A (en) 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
AU696387B2 (en) 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
EP0871671A1 (en) 1995-09-07 1998-10-21 PPL Therapeutics (Scotland) Limited Purification of alpha-1 proteinase inhibitor
US5780440A (en) 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
SI20413A (sl) 1998-03-16 2001-06-30 Inhale Therapeutic Systems, Inc. Dajanje aerosoliziranega aktivnega sredstva
US6093804A (en) 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US6397838B1 (en) 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
DE19953317C1 (de) * 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
CA2430973A1 (en) 2000-12-18 2002-06-27 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
SI1664123T2 (sl) 2003-09-22 2012-03-30 Kamada Ltd Priprava inhibitorja alfa proteinaze v velikem merilu in njegova uporaba
SI1684719T1 (sl) 2003-11-14 2012-07-31 Baxter Int Sestavki alfa antitripsina in postopki zdravljenja ob uporabi takih sestavkov
AU2005221151A1 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
CA2641872A1 (en) * 2006-02-09 2007-08-16 Kamada Ltd. Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases
US20080078382A1 (en) 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
EP1927373B1 (en) 2006-11-30 2012-08-22 PARI Pharma GmbH Inhalation nebulizer
CN102099369A (zh) 2008-07-18 2011-06-15 泰勒克里斯生物治疗学公司 制备α-1蛋白酶抑制剂的方法
EP2496246B1 (en) 2009-11-03 2018-06-27 Grifols Therapeutics LLC Composition, method, and kit for alpha-1 proteinase inhibitor

Also Published As

Publication number Publication date
CA2844878C (en) 2017-11-28
JP2017039745A (ja) 2017-02-23
KR20140108516A (ko) 2014-09-11
AR116887A2 (es) 2021-06-23
ES2887358T3 (es) 2021-12-22
CN103889436A (zh) 2014-06-25
MX351189B (es) 2017-10-04
MY166314A (en) 2018-06-25
US9421248B2 (en) 2016-08-23
SG2014012066A (en) 2014-09-26
BR112014007127A2 (pt) 2017-04-04
RU2014106758A (ru) 2015-08-27
JP2015504051A (ja) 2015-02-05
NZ621596A (en) 2016-08-26
IL231109B (en) 2018-02-28
MX2014001764A (es) 2014-04-30
US20150011460A1 (en) 2015-01-08
RU2635482C2 (ru) 2017-11-13
CL2014000722A1 (es) 2014-10-10
WO2013098672A3 (en) 2013-10-24
AU2012337241A1 (en) 2013-07-18
IL231109A0 (en) 2014-04-30
EP2758065B1 (en) 2021-06-23
EP2758065A2 (en) 2014-07-30
AU2012337241B2 (en) 2016-10-13
HK1198918A1 (en) 2015-06-19
CA2844878A1 (en) 2013-07-04
WO2013098672A2 (en) 2013-07-04
AR088971A1 (es) 2014-07-23
JP2018104439A (ja) 2018-07-05
SG10201610913PA (en) 2017-02-27
JP2019135243A (ja) 2019-08-15
CN107596359A (zh) 2018-01-19

Similar Documents

Publication Publication Date Title
CR20150507A (es) Inhibidores de histona desmetilasas
SMT201700109B (it) Inibitori di istone demetilasi
HK1213251A1 (zh) 作為突變 抑制劑的 -嘧啶- -基-噁唑烷- -酮化合物
CR20140024A (es) Compuestos inhibidores de metaloenzimas
BR112013028235A2 (pt) refrigerador
BR112013028281A2 (pt) compostos e composições para inibição de nampt
TWD180147S (zh) 淨水器
UY34654A (es) Inhibidores de la beta-secretasa
UY34465A (es) ?inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares?.
CO7020915A2 (es) Inhibidores de iap
DK2753672T3 (da) Bifunktionelle tilsætningsstoffer til hæmning af afsætning af mineraler og til hæmning af korrosion
HK1219273A1 (zh) 磷酸二酯酶 型的新型抑制劑化合物
DK3240767T3 (da) Mikroindkapslede nitrifikationshæmmersammensætninger
DK3562487T3 (da) Metalloenzyminhibitorforbindelser
DK3137437T3 (da) Mikroindkapslet nitrifikationsinhibitorsammensætning
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
DK2500036T3 (da) MET-hæmmere til øgning af virkningen af radioterapi
ITRM20120277A1 (it) Procedimento per ridurre la larghezza di incrinature.
EA201790428A1 (ru) Синтез энт-прогестерона и его промежуточных соединений
EA201690749A1 (ru) Новые ингибиторы sglt1
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.
GB2523615B (en) Use of Naphthalene-1,4-diketone compound as hCBS enzyme inhibitor
FR2973705B1 (fr) Inhibiteur de tnf-alpha.
GB201312311D0 (en) Uses of enzyme inhibitors

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211014